# High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer

> **NCT01646034** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 74 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** carboplatin, thiotepa, and cyclophosphamide
- **DRUG:** chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)

## Key facts

- **NCT ID:** NCT01646034
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-09
- **Primary completion:** 2023-01
- **Final completion:** 2026-10
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01646034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01646034, "High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01646034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*